SAN DIEGO, January 18, 2022–(BUSINESS WIRE)–PhenoVista Biosciences today announced that it has secured funding from BroadOak Capital Partners, a life sciences-focused investor. Since its creation in 2014, PhenoVista has democratized access to high-content analysis of physiologically relevant cellular models. The investment will be used to develop complex new products, such as models of the blood-brain barrier and platforms to better understand neurodegenerative diseases.
“The funding provided by our partners at BroadOak will allow us to accelerate our growth by continuing to invest in our passion – providing our customers with data from cutting-edge cellular models that are not available from any other service provider,” said James G. Evans, CEO and co-founder of PhenoVista. “Most importantly, by increasing our resources, we can deliver impactful information to more customers faster than ever before, increasing the value of our contribution to global health.”
The PhenoVista team is made up of experts in various fields, such as imaging, assay development, high-throughput and high-content data analysis, microfluidics, machine learning and AI. , and advanced cell culture, including primary cells, neurons, organoids and spheroids. The team’s broad, deep and versatile skillset uniquely positions the company to meet challenges in all areas of biology, from immunology and fibrosis to neurodegenerative diseases.
PhenoVista has demonstrated its expertise and experience in successfully addressing the complex challenges of its customers’ research projects, including test development for small and large biotech and pharmaceutical companies as well as government agencies. To date, they have developed over 100 different phenotypic tests through their flexible style of engaging with customers to meet their needs.
The demand from the drug discovery industry for increasing amounts of bespoke services is accelerating growth opportunities for PhenoVista. With funding from BroadOak, PhenoVista will continue to stay at the forefront of imaging and data analysis methods and create new models of biological systems in growing areas of interest. These advances will provide scientists with new strategies to improve drug discovery processes and better understand biological phenomena, thereby improving healthcare options for patients worldwide.
About PhenoVista Biosciences
PhenoVista Biosciences is a leading provider of personalized, imaging-based phenotypic testing services based in San Diego, CA. PhenoVista has built a strong reputation globally for delivering high quality data with a collaborative and adaptable nature of engagement to biopharmaceutical customers ranging from local start-ups to multinational organizations. Their diverse repertoire includes working with primary cells, iPSC-derived neurons, and customer-designed lines in 2D, 3D, co-culture, and microfluidic systems to construct a myriad of functional, structural, and preclinical therapeutic assays. . For more information, visit http://www.phenovista.com.
About BroadOak Capital Partners
BroadOak Capital Partners, headquartered in Washington, D.C. and San Francisco, is a life sciences financial institution that provides direct investment and investment banking services to businesses in the areas of research and consumables, diagnostics, biopharmaceutical services and adjacent markets. BroadOak has led or participated in investments in over 50 companies in their niche across multiple funds and investment vehicles. For more information, visit www.broadoak.com.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220118005244/en/